RFL
Rafael Holdings, Inc.
NYSE · Real Estate · Real Estate - Services · US
$1.29
−7.19%Sep 30, 2026, 11:25 UTC
Rafael Holdings, Inc. reported preliminary Q3 2026 results, disclosing clinical trial data including an overall survival hazard ratio of 0.154 in the INPDR group and 0.057 in the expanded group.
Sep 30, 2026, 11:00 UTC
Rafael Holdings announced topline results from the pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C, reporting that the drug missed statistical significance on the primary endpoint but showed a directionally favorable treatment effect.
Source:Jul 20, 2026, 13:30 UTC
Rafael Chairman Yuval Steinitz announces plans to expand the company's presence in the U.S., Germany, and India, including production and R&D facilities.
Source:Jul 20, 2026, 13:30 UTC
Rafael Chairman Yuval Steinitz calls for the Israeli government to advance plans for a partial privatization of Rafael.
Source:Jun 11, 2026, 00:00 UTC
Rafael Holdings, Inc. reported financial results for the third quarter of fiscal year 2026, with revenue of $179,000 and a net loss of $4,226,000 (or $0.08 per diluted share).
Jun 10, 2026, 11:30 UTC
Rafael Holdings completed the last patient last visit for its Phase 3 TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C.
Source: